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Abstract

Purpose: Inverse planning simulated annealing (IPSA) optimized brachytherapy treatment plans are
characterized with large isolated dwell times at the first or last dwell position of each catheter. The potential of
catheter shifts relative to the target and organs at risk in these plans may lead to a more significant change in
delivered dose to the volumes of interest relative to plans with more uniform dwell times. Material and
methods: This study aims to determine if the Nucletron Oncentra dwell time deviation constraint (DTDC)
parameter can be optimized to improve the robustness of high-dose-rate (HDR) prostate brachytherapy plans
to catheter displacements. A set of 10 clinically acceptable prostate plans were re-optimized with a DTDC
parameter of 0 and 0.4. For each plan, catheter displacements of 3, 7, and 14 mm were retrospectively applied
and the change in dose volume histogram (DVH) indices and conformity indices analyzed. Results: The
robustness of clinically acceptable prostate plans to catheter displacements in the caudal direction was found
to be dependent on the DTDC parameter. A DTDC value of 0 improves the robustness of planning target
volume (PTV) coverage to catheter displacements, whereas a DTDC value of 0.4 improves the robustness of
the plans to changes in hotspots. Conclusions: The results indicate that if used in conjunction with a pretreatment catheter displacement correction protocol and a tolerance of 3 mm, a DTDC value of 0.4 may
produce clinically superior plans. However, the effect of the DTDC parameter in plan robustness was not
observed to be as strong as initially suspected.
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Abstract
Purpose: Inverse planning simulated annealing (IPSA) optimized brachytherapy treatment plans are characterized
with large isolated dwell times at the first or last dwell position of each catheter. The potential of catheter shifts relative
to the target and organs at risk in these plans may lead to a more significant change in delivered dose to the volumes
of interest relative to plans with more uniform dwell times.
Material and methods: This study aims to determine if the Nucletron Oncentra dwell time deviation constraint
(DTDC) parameter can be optimized to improve the robustness of high-dose-rate (HDR) prostate brachytherapy plans
to catheter displacements. A set of 10 clinically acceptable prostate plans were re-optimized with a DTDC parameter
of 0 and 0.4. For each plan, catheter displacements of 3, 7, and 14 mm were retrospectively applied and the change in
dose volume histogram (DVH) indices and conformity indices analyzed.
Results: The robustness of clinically acceptable prostate plans to catheter displacements in the caudal direction
was found to be dependent on the DTDC parameter. A DTDC value of 0 improves the robustness of planning target
volume (PTV) coverage to catheter displacements, whereas a DTDC value of 0.4 improves the robustness of the plans
to changes in hotspots.
Conclusions: The results indicate that if used in conjunction with a pre-treatment catheter displacement correction
protocol and a tolerance of 3 mm, a DTDC value of 0.4 may produce clinically superior plans. However, the effect of
the DTDC parameter in plan robustness was not observed to be as strong as initially suspected.
J Contemp Brachytherapy 2016; 8, 3: 203–209
DOI: 10.5114/jcb.2016.60499
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Purpose
Prostate cancer is the most common male malignancy in the Western world, and as life expectancy increase,
the prevalence is also expected to increase in an aging
population [1]. Radiotherapy is an important therapeutic
modality for the treatment of patients with localized or
locally advanced prostate cancer [2] utilizing both external beam radiotherapy (EBRT) and brachytherapy. Over
the last few decades, significant advances in technology
related to high-dose-rate (HDR) brachytherapy have seen
an increase in its use as a localized boost to EBRT of the
prostate.
An important technological advancement in HDR
brachytherapy is the evolution from forward planning to
inverse planning techniques [3,4,5]. The inverse planning
optimization algorithm currently implemented in the Nu-

cletron Oncentra (Nucletron B.V., Veenendaal, The Netherlands) brachytherapy treatment planning system (TPS)
is the inverse planning simulated annealing (IPSA) optimization algorithm. Inverse planning simulated annealing
is based on contoured anatomy and optimizes dwell times
using a simulated annealing algorithm [6]. The algorithm
is constrained by user specific surface and volumetric dose
constraints for both the target volume and organs at risk to
calculate clinically acceptable treatment plans [7].
Inverse planning simulated annealing optimized
brachytherapy treatment plans are characterized with
large isolated dwell times at the first or last dwell position of each catheter. The central dwell positions however consist of extremely short, or zero, dwell times [8].
There is concern amongst users that these large isolated
dwell times may lead to hot spots, either inside or outside
the target. Also, the potential of catheter shifts relative to
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the target and organs at risk may lead to a more significant change in delivered dose to the volumes of interest
relative to plans with more uniform dwell times. Recently, the Nucletron Oncentra TPS has added the dwell time
deviation constraint (DTDC) parameter to the IPSA optimization process. This parameter constrains the allowable
dwell times in the optimization process and can be set to
a value between 0 and 1 in increments of 0.1. A value of
0 corresponds to completely unrestricted dwell times and
a value of 1 results in homogeneous dwell times [9].
The displacement of catheters relative to the target and
organs at risk during the time between imaging and patient treatment has been reported by a number of groups
[10,11,12,13]. The displacements have predominantly
been reported along the patient longitudinal axis and in
the caudal direction [10] primarily due to acute edema
between the prostate and perineal skin [14]. Previous
work from our group [11] demonstrated a median catheter displacement of 7.5 mm in caudal direction (range
2.9-23.9 mm) in the time from planning CT to treatment
(approximately 1-3 hours). Tiong et al. [10] have reported
significant adverse effects on the tumor control probability for catheter displacements larger than 3 mm, including underdosage of the target and overdosage to critical
structures. Due to these findings, our department has implemented a clinical protocol, in which internal catheter
positions are verified and corrected immediately prior to
treatment delivery with a tolerance of 3 mm.
This study aims to determine if the DTDC parameter
can be optimized to improve the robustness of HDR prostate brachytherapy plans to catheter displacements relative to patient anatomy. A set of 10 clinically acceptable
prostate plans were re-optimized with a DTDC parameter of 0 and 0.4. The values of 0 and 0.4 were chosen to
reflect the change that is currently occurring in our clinical protocol. For each plan, catheter displacements of 3, 7,
and 14 mm were retrospectively applied, and the change
in DVH indices and conformity indices analyzed.

same radiation oncologist at the time of treatment. Prostate volumes varied between 25.1 and 59.4 cm3 and the
number of catheters used was between 14 and 24. All patients received 2 fractions of 9.5 Gy with 2 weeks between
fractions. Catheter insertion (using Oncosmart, ProGuide
Sharp Needle, 6F, Nucletron B.V., Veenendaal, The Netherlands), CT scan, planning, and treatment are all performed on the same day, and the mean time between the
planning CT and treatment was 182 minutes.

IPSA optimization and DTDC
Each plan was optimized using the IPSA algorithm
using the parameters outlined in Table 1. As per clinical
protocol, plans were initially optimized with the DTDC
parameter set to 0. The plans were then re-optimized with
the DTDC parameter set to 0.4 and all other parameters
kept constant. The dwell time characteristics of each plan
were then compared using the plan modulation index
(M), as defined by Smith et al. [9]. The plan modulation
index is defined as the maximum deviation of dwell time
from the average dwell time for each catheter, normalized to the maximum dwell time for the treatment plan,
averaged over all catheters in the plan.

Catheter displacements
Catheter displacements in the caudal direction were
then simulated for each plan. Offsets of 3, 7, and 14 mm
were performed. Displacements of this magnitude were
chosen as they corresponded to clinically relevant catheter displacements, as found in a previous study by our
group [11]. Our center has implemented a clinical protocol, in which catheter displacements ≥ 3 mm are corrected for, immediately prior to treatment by altering the
indexer length at the treatment console. Implanting the
catheters past the prostate base into the bladder allowed
for extra dwell positions beyond the prostate in the event
of a caudal shift. Physical re-insertion was not performed.

Plan analysis

Material and methods
Initial plans
A set of 10 clinical prostate HDR brachytherapy plans
were chosen for analysis. These CT plans were created between 2012 and 2015 on the Nucletron Oncentra
Brachytherapy TPS (v4.3, Nucletron B.V., Veenendaal,
The Netherlands). The prostate planning target volume
(PTV), urethra, and rectum were all contoured by the

All patient plans were assessed by evaluating dose
volume histogram (DVH) indices and dose quality indices. Dose volume histogram indices used for plan evaluation are outlined in Table 2. Furthermore, a normal tissue (NT) contour was created by adding a 2 mm margin
around the PTV and subtracting this expanded contour
from the external contour, e.g. NT = Body – (PTV + 2 mm).
These parameters were automatically calculated by the

Table 1. Inverse planning simulated annealing (IPSA) optimization parameters used for patient plan optimization
ROI

Usage

Prostate

PTV

Rectum

Organ

Urethra

Organ

Surface

Volume

Weight

Min (cGy)

Max (cGy)

Weight

Weight

Min (cGy)

Max (cGy)

Weight

100

950

1425

100

100

100

950

30

665

50

50

475

50

998

50

50

998

50

120

950

950

PTV – planning target volume
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TPS and are highly dependent on the size of the histogram bin used for calculation [8]. Because of this, a conformity index (CI), a dose inhomogeneity index (DHI),
and an overdose volume index (ODI) were also calculated for each plan.
The CI used in this study is the one introduced by
van’t Riet et al. [15] and is shown in Equation 1:
V
V
CI = T,ref × T,ref 
VT
Vref

(1),

where VT,ref is the volume of the PTV receiving a dose
greater than or equal to the 100% isodose, VT is the volume of the PTV, and Vref is the volume of the 100% isodose. The DHI parameter gives an indication of the homogeneity of the dose within the PTV, which was first
introduced by Wu et al. [16] and is shown in Equation 2:
DHI =

VT,ref – VT,1.5ref
VT,ref


(2),

where VT,1.5ref is the volume of the PTV receiving a dose
greater than or equal to the 150% isodose, and VT,ref is as
described above. Finally, the ODI parameter [17] indicates the amount of high dose (greater than 200%) within
the PTV:
ODI =

VT,2ref
VT,ref 

(3),

where VT,2ref is the volume of the PTV receiving a dose
greater than or equal to the 200% isodose.
The change in DVH and dose quality indices was then
calculated as a function of catheter displacement for both
DTDC values of 0 and 0.4. The change in these indices
with increasing catheter displacement gives an indication
of the robustness of the plans to changes in catheter po-

Table 3. Plan modulation index (M) and normalized total dwell time (cGy-1cm-2)
Patient

Plan modulation index
(M)
DTDC 0

DTDC 0.4

Normalized total dwell
time (cGy-1cm-2)
DTDC 0
10-6

Table 2. Clinically acceptable dose volume histogram (DVH) indices
Volume type

Dose (%)

Dose (cGy)

Volume (%)

PTV

100

950

≥ 90

PTV

150

1425

< 30

PTV

200

1900

< 15

Rectum

70

665

0

Urethra

120

1140

0

PTV – planning target volume

sition relative to the targets and organs at risk between
planning CT and treatment. Statistical significance between the DTDC values was verified using a paired t-test
with α = 0.05 (corresponding to a 5% significance level).

Results
Initial clinical plans
Initial clinical prostate plans IPSA optimized with
a DTDC value of 0 produced a large spread of dwell
times, relative to those plans optimized with a DTDC
value of 0.4. The plan modulation index (M) for each
plan variant is given in Table 3 along with the total dwell
time, normalized to the air kerma strength of the source.
The average M for the 0 DTDC case (± 1 SD) was equal
to 0.44 ± 0.07, whereas for the 0.4 DTDC case M = 0.20
± 0.06. The effect of increasing the DTDC parameter is
to limit the maximum dwell time in any catheter; this is
reflected by the decreasing value of M, as more homogeneous dwell time distribution is created within each cath-

Table 4. Initial dose volume histogram (DVH) and
dose indices before catheter displacement
Parameter

DTDC 0

DTDC 0.4

p

PTV V100%

92.9 ± 1.9%

93.4 ± 1.7%

≤ 0.2620

PTV V150%

18.9 ± 3.6%

23.0 ± 3.7%

≤ 0.0001

PTV V200%

7.5 ± 1.6%

9.0 ± 1.4%

≤ 0.0002

10-6

Rectum V70%

0.1 ± 0.1%

0.1 ± 0.1%

≤ 0.3498

DTDC 0.4

1

0.48

0.09

8.32 ×

2

0.34

0.23

2.75 × 10-6

2.55 × 10-6

Urethra V120%

10.4 ± 5.6%

5.9 ± 5.9%

≤ 0.0421

0.25

10-6

2.33 ×

10-6

NT V100%

11.0 ± 3.0 cc

5.7 ± 1.9 cc

≤ 0.0001

9.82 ×

10-6

NT V150%

3.3 ± 1.4 cc

1.2 ± 0.7 cc

≤ 0.0001

14.32 ×

10-6

NT V200%

1.5 ± 0.2 cc

0.5 ± 0.3 cc

≤ 0.0018

3
4

0.43
0.41

0.23

2.57 ×

10.44 ×

10-6
10-6

7.73 ×

5

0.57

0.17

15.27 ×

6

0.43

0.18

12.45 × 10-6

12.34 × 10-6

CI

0.691 ± 0.046

0.748 ± 0.042

≤ 0.0002

0.24

6.32 ×

10-6

6.12 ×

10-6

DHI

0.204 ± 0.039

0.246 ± 0.038

≤ 0.0001

8.72 ×

10-6

8.29 ×

10-6

ODI

0.081 ± 0.018

0.097 ± 0.014

≤ 0.0004

10-6

7.80 ×

10-6

7
8

0.42
0.48

0.19

9

0.40

0.21

8.37 ×

10

0.44

0.20

7.27 × 10-6

DTDC – dwell time deviation constraint

6.80 × 10-6

PTV – planning target volume, NT – normal tissue, CI – conformity index,
DHI – dose inhomogeneity index, ODI – overdose index, V100%, V150%, V200%,
V70%, V120% – volume of relevant structure receiving 100%, 150%, 200%, 70%,
and 120% of the prescribed isodose, respectively, DTDC – dwell time deviation
constraint
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Table 5. Change in dose volume histogram (DVH)
and dose indices for a 3 mm catheter displacement
Parameter

DTDC 0

DTDC 0.4

p

PTV V100%

0.788 ± 0.751%

–1.299 ± 0.916%

≤ 0.0001

PTV V150%

1.786 ± 1.540%

0.146 ± 0.537%

≤ 0.0009

PTV V200%

1.051 ± 0.829%

–0.034 ± 0.183%

≤ 0.0021

Rectum V70%

0.078 ± 0.081%

0.080 ± 0.090%

≤ 0.8905

Urethra V120% –5.628 ± 4.878%

–4.019 ± 5.047%

≤ 0.0088

NT V100%

–1.042 ± 1.314 cc

1.314 ± 1.661 cc

≤ 0.0454

NT V150%

–1.033 ± 0.893 cc 0.468 ± 0.504 cc

≤ 0.0001

NT V200%

–0.568 ± 0.674 cc

0.171 ± 0.318 cc

≤ 0.0052

CI

0.002 ± 0.017

–0.024 ± 0.022

≤ 0.0011

DHI

0.017 ± 0.005

0.005 ± 0.006

≤ 0.0033

ODI

0.011 ± 0.008

0.001 ± 0.002

≤ 0.0035

the coverage of the PTV is improved, as reflected by the
increase in PTV V100% and CI, however, only the difference in CI was found to be statistically significant. Statistically significant reductions in NT V100%, NT V150%, and
NT V200% were also found when changing DTDC from 0
to 0.4. This, along with the improvement in CI, is due to
the reduction in the large isolated dwell times just outside
of the PTV, which are delivering higher doses to the adjacent healthy tissue. On the other hand, there is a statistically significant increase in PTV V150%, PTV V200%, DHI,
and ODI for DTDC 0.4 versus DTDC 0. The rectum V150%
was largely unaffected by the DTDC change, and a small
reduction in the urethra V120% was observed.

Effect of catheter displacements

eter. The total dwell time, normalized to the air kerma
strength of the source was also seen to decrease for plans
optimized with a DTDC value of 0.4, relative to a DTDC
of 0. This is due to the reduction in large isolated dwell
times at the first or last dwell positions of each catheter.
Table 4 shows the change in DVH and dose quality indices when re-optimizing the plans with a DTDC
parameter of 0.4. By changing the DTDC value to 0.4,

The effect of catheter displacements on DVH and
dose quality indices are shown in Tables 5, 6, and 7 for
catheter shifts of 3, 7, and 14 mm, respectively. Overall,
a DTDC value of 0 improves the robustness of PTV coverage to catheter displacements relative to a DTDC value of
0.4. This is reflected in the smaller changes in PTV V100%
(Figure 1) and CI (Figure 2) for all three catheter displacement values. The dwell positions moving out of the PTV
in the DTDC 0 plans have smaller weights relative to
those in the DTDC 0.4 plans, resulting in smaller changes
in PTV V100% and CI with catheter displacement.
Conversely, a DTDC value of 0.4 improves the robustness of the plans to changes in hotspots, reflected by statistically significant differences in changes to PTV V150%,
PTV V200% (Figure 3), DHI, and ODI (Figure 4) compared
to plans optimized with a DTDC value of 0 for catheter
displacements up to 14 mm. This behavior can be explained by considering that the isolated dwell times at the
end of the catheters often exist just outside the PTV be-

Table 6. Change in dose volume histogram (DVH)
and dose indices for a 7 mm catheter displacement

Table 7. Change in dose volume histogram (DVH)
and dose indices for a 14 mm catheter displacement

PTV – planning target volume, NT – normal tissue, CI – conformity index,
DHI – dose inhomogeneity index, ODI – overdose index, V100%, V150%, V200%,
V70%, V120% – volume of relevant structure receiving 100%, 150%, 200%, 70%,
and 120% of the prescribed isodose, respectively, DTDC – dwell time deviation
constraint

Parameter

DTDC 0

DTDC 0.4

p

Parameter

DTDC 0

DTDC 0.4

p

PTV V100%

–2.803 ± 2.516%

–8.99 ± 2.283%

≤ 0.0001

PTV V100%

–18.69 ± 5.197%

–25.74 ± 5.313%

≤ 0.0003

PTV V150%

2.199 ± 2.670%

–1.262 ± 1.158%

≤ 0.0002

PTV V150%

0.522 ± 3.343%

–3.589 ± 2.063%

≤ 0.0001

PTV V200%

1.255 ± 1.260%

–0.689 ± 0.427% ≤ 0.0008

PTV V200%

0.566 ± 1.455%

–1.628 ± 0.786%

≤ 0.0005

Rectum V70%

0.271 ± 0.324%

0.265 ± 0.324%

≤ 0.7793

Rectum V70%

0.690 ± 0.917%

0.665 ± 0.956%

≤ 0.4049

Urethra V120% –6.461 ± 5.879%

–4.333 ± 6.804%

≤ 0.0205

Urethra V120% –4.657 ± 7.543% –0.592 ± 10.624% ≤ 0.0523

NT V100%

1.072 ± 3.121 cc

4.381 ± 1.996 cc

≤ 0.0189

NT V100%

8.928 ± 4.198 cc

NT V150%

–0.399 ± 1.639 cc

1.507 ± 0.753 cc

≤ 0.0041

NT V150%

1.582 ± 1.210 cc

3.981 ± 1.197 cc

≤ 0.0008

NT V200%

–0.471 ± 0.940 cc

0.641 ± 0.517 cc

≤ 0.0014

NT V200%

0.453 ± 0.786 cc

1.756 ± 0.747 cc

≤ 0.0036

CI

–0.046 ± 0.044

–0.136 ± 0.046

≤ 0.0005

CI

–0.251 ± 0.072

–0.352 ± 0.064

≤ 0.0003

DHI

0.029 ± 0.024

0.011 ± 0.016

≤ 0.0007

DHI

0.056 ± 0.040

0.041 ± 0.039

≤ 0.0013

ODI

0.016 ± 0.012

0.002 ± 0.004

≤ 0.0020

ODI

0.027 ± 0.018

0.013 ± 0.010

≤ 0.0043

PTV – planning target volume, NT – normal tissue, CI – conformity index,
DHI – dose inhomogeneity index, ODI – overdose index, V100%, V150%, V200%,
V70%, V120% – volume of relevant structure receiving 100%, 150%, 200%, 70%,
and 120% of the prescribed isodose, respectively, DTDC – dwell time deviation
constraint

13.495 ± 2.333 cc ≤ 0.0002

PTV – planning target volume, NT – normal tissue, CI – conformity index,
DHI – dose inhomogeneity index, ODI – overdose index, V100%, V150%, V200%,
V70%, V120% – volume of relevant structure receiving 100%, 150%, 200%, 70%,
and 120% of the prescribed isodose, respectively, DTDC – dwell time deviation
constraint
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3

Change in PTV V200 (%)

Change in PTV V100 (%)

0
–5
–10
–15
–20
–25
–30
–35

0

2

4

6

8

10

12

14

2
1
0
–1
–2
–3

16

0

2

DTDC 0.4

DTDC 0

8

10

12

14

Fig. 2. The change in PTV V200% as a function of catheter
displacement for plans optimized with DTDC set to 0 and
0.4 (error bars showing 95% confidence interval)

0.05

0.055

0.00

0.045
Change in ODI

–0.10
–0.15
–0.20
–0.25
–0.30
–0.35

0.035
0.025
0.015
0.005

–0.40
–0.45

16

DTDC 0.4

Fig. 1. The change in PTV V100% as a function of catheter
displacement for plans optimized with DTDC set to 0 and
0.4 (error bars showing 95% confidence interval)

–0.05
Change in CI

6

Catheter displacement (mm)

Catheter displacement (mm)
DTDC 0

4

0

2

4

6

8

10

12

14

16

–0.005

0

Catheter displacement (mm)
DTDC 0

2

4

6

8

10

12

14

16

Catheter displacement (mm)

DTDC 0.4

DTDC 0

DTDC 0.4

Fig. 3. The change in CI as a function of catheter displacement for plans optimized with DTDC set to 0 and 0.4 (error
bars showing 95% confidence interval)

Fig. 4. The change in ODI as a function of catheter displacement for plans optimized with DTDC set to 0 and 0.4
(error bars showing 95% confidence interval)

fore a catheter shift is implemented. Therefore, the V150%
and V200% volumes are surrounding these dwell positions
and, as a catheter shift is implemented, they move further
away from the PTV and into healthy tissue.
For a catheter displacement of 3 mm, plans optimized
with a DTDC value of 0.4 were found to be more robust in
terms of NT V100%, NT V150%, and NT V200%. Conversely,
for larger catheter shifts of 7 and 14 mm, the plans optimized with DTDC 0 were more robust. This is due to
the fact that for a catheter shift of 3 mm, one of the large
isolated dwell positions in the DTDC 0 plans moves into
the normal tissue. However, for larger shifts, subsequent
dwell positions moving into the normal tissue have significantly smaller dwell times compared to those in the
DTDC 0.4 plans, resulting in smaller changes in NT V100%,
NT V150%, and NT V200%.

The urethra V120% was more sensitive to catheter
displacements than the rectum V70% for both values of
DTDC. A DTDC value of 0.4 improved the robustness of
the plans to changes in urethra V120% compared to plans
optimized with a DTDC value of 0, with statistically significant differences for catheter displacements of 3 and
7 mm. There was also no statistically significant difference found between DTDC values for the rectum V70%.

Discussion
As expected, the plan modulation index (M) was
observed to decrease with an increased value of DTDC.
The calculated values of M = 0.44 ± 0.07 (DTDC = 0) and
M = 0.20 ± 0.06 (DTDC = 0.4) are in close agreement with
those found in a previous study by Smith et al. [9]. The in-
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crease value of DTDC was also observed to increase the
PTV V100%, V150%, and V200%. The increase in PTV V150% of
4% and PTV V200% of 1.5% when changing the DTDC value
from 0 to 0.4 was also observed in the same study [9]. This
increase resulted in DVH indices that were still clinically
acceptable for treatment according to our local protocol as
outlined in Table 2.
Contrary to expectation, the DTDC value of 0 produced plans that were more robust to catheter displacements in terms of target coverage. However, for a catheter
displacement of 3 mm, the average CI was 0.693 ± 0.049
and 0.723 ± 0.045 for DTDC = 0 and DTDC = 0.4, respectively. Our center has implemented a clinical protocol, in
which catheter displacements ≥ 3 mm are corrected for,
immediately prior to treatment by adjusting the indexer length on the treatment control system. Therefore, if
used in combination with this catheter correction protocol, plans optimized with a DTDC value of 0.4 may be
clinically superior to those optimized with DTDC = 0,
especially when considering that using a DTDC value of
0.4 improves robustness to changes in hotspots and dose
to OARs and healthy tissue.
One recent advance in the field of HDR prostate
brachytherapy has been the use of 3D trans-rectal ultrasound (TRUS) based treatment planning [18]. The use of
this technique has been shown to significantly reduce
the time between imaging and treatment compared to
CT based treatment planning. Milickovic et al. [18] have
shown that for an average time between imaging and
treatment of 51.2 minutes, the average needle displacement was found to be 1 mm. This displacement is small
relative to those noted in other studies [11,14], and is
likely due to the reduction in time between imaging and
treatment. Therefore, one current initiative of our group
is to reduce the time between imaging and treatment, and
the introduction of 3D TRUS based planning is being investigated.
A previous study by our group [11] has shown that
catheter displacements in the cranial direction occurred
for only 3 of 48 cases, with the remainder occurring in
the caudal direction. One limitation of this study is that
catheter displacements were only considered along the
longitudinal axis in the caudal direction. Catheter shifts
in the lateral and anterior-posterior directions due to edema were also not considered.
A further limitation is that only two values of DTDC
were considered. Preliminary calculations showed that
small changes in DTDC, e.g. from 0.2-0.4 do not significantly affect the robustness of the plans to catheter displacements. Furthermore, values of 0 and 0.4 were chosen to reflect the change that is currently occurring in our
clinical protocol. Historically, plans have been optimized
using a DTDC value of 0; however previous studies [9]
have shown that a DTDC value of 0.4 gives plan modulation equivalent to graphical optimization without significantly compromising plan quality.

Conclusions
The results of this study indicate that the robustness
of clinically acceptable prostate plans to catheter displace-

ments in the caudal direction are dependent on the DTDC
parameter. A DTDC value of 0 improves the robustness
of PTV coverage to catheter displacements relative to
a DTDC value of 0.4. Whereas a DTDC value of 0.4 improves the robustness of the plans to changes in hotspots
compared to a DTDC value of 0. For a catheter displacement of 3 mm, plans optimized with a DTDC value of
0.4 were found to be more robust in terms of the dose
to normal tissue. However, for larger catheter shifts, the
plans optimized with DTDC 0 were more robust, due to
larger shifts moving relatively small weight dwell positions into the normal tissue compared to the DTDC 0.4
plans. When used in combination with a pre-treatment
catheter displacement correction protocol and a tolerance
of 3 mm, a DTDC value of 0.4 may produce clinically superior plans.
In future work, attempts will be made to measure the
actual dwell times delivered by the afterloader as compared to those calculated by the TPS for a range of DTDC
values and the effect on the dose examined.
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